{"entity":{"id":"arlocabtagene-autoleucel","kind":"drug","name":"Arlocabtagene Autoleucel","aka":["Arlo-cel","GPRC5D CAR T cells"],"tldr":"Arlocabtagene Autoleucel is an experimental CAR-T cell therapy from Juno Therapeutics, a Bristol-Myers Squibb in phase 3 trials for multiple myeloma, aimed at GPRC5D.","summary":"Arlocabtagene Autoleucel (CC-95266, BMS-986393) is a CAR-T cell therapy developed by Juno Therapeutics, a Bristol-Myers Squibb. Its target is GPRC5D (the sponsor names GPRC5D). The sponsor states: Arlocabtagene autoleucel (BMS-986393, CC-95266) is a GPRC5D-directed CAR T cell therapy, engineered to target GPRC5D-expressing myeloma cells, given as an infusion to heavily pretreated relapsed/refractory multiple myeloma patients. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06615479 (A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)), in multiple myeloma. The largest, NCT06615479, plans to enrol 440 participants with primary completion expected 2027-12-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Arlocabtagene Autoleucel","url":"https://clinicaltrials.gov/search?intr=CC-95266"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":["gprc5d"],"drugs":[],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":["quintessential-2","nct06297226"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"CC-95266, BMS-986393","modality":"CAR-T cell therapy","mechanism":"Arlocabtagene autoleucel (BMS-986393, CC-95266) is a GPRC5D-directed CAR T cell therapy, engineered to target GPRC5D-expressing myeloma cells, given as an infusion to heavily pretreated relapsed/refractory multiple myeloma patients.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/arlocabtagene-autoleucel/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"target":[{"id":"gprc5d","kind":"target","name":"GPRC5D","route":"/targets/gprc5d/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}],"trial":[{"id":"quintessential-2","kind":"trial","name":"A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)","route":"/trials/quintessential-2/"},{"id":"nct06297226","kind":"trial","name":"Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct06297226/"}]}}